perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Published benefits of ivermectin use in Itajaí, Brazil for COVID-19 infection, hospitalisation, and mortality are entirely explained by statistical artefacts

- 🔞 Robin Mills ^{© 1}, Ana Carolina Peçanha Antonio ^{© 2}, Greg Tucker-Kellogg ^{© 3}
- ⁷ ¹Al Horizon, The Netherlands; ²Adult Intensive Care Unit, Hospital de Clínicas de
- Porto Alegre, Brazil; ³Department of Biological Sciences, National University of
- Singapore, Singapore

☑ For correspondence: dbsgtk@nus.edu.sg

Data and code availability:

All data is publicly available from previous publications or public databases of the Brazil Ministry of Health. Links are provided at the end of the Methods section. Source code to reproduce the analyses here is available at https://github.com /gtuckerkellogg //tajai-reanalysis.

Funding: No funding was received for this work.

Competing interests: GTK receives revenue from YouTube for content on scientific misinformation and received conference travel support from the Institute for Clinical Research (Malaysia) for a talk given at the 15th National Conference for Clinical Research (NCCR). ACPA and RM declare no competing interests.

Ethics approval: The

Institutional Review Board of the National University of Singapore waived ethical approval of this work based on sole use of previously approved and publicly available subject data. Reference NUS-IRB-2023-474.

Abstract

10

11

12 Background

- Two recent publications by Kerr et al. (Cureus 14(1):e21272; Cureus 14(8): e28624) reported
 dramatic effects of prophylactic ivermectin use for both prevention of COVID-19 and
 reduction of COVID-19-related hospitalisation and mortality, including a dose-dependent
 effect of ivermectin prophylaxis. These papers have gained an unusually large public
 influence: they were incorporated into debates around COVID-19 policies and may have
- contributed to decreased trust in vaccine efficacy and public health authorities more broadly.
 Both studies were based on retrospective observational analysis of city-wide registry data
- ²⁰ from the city of Itajaí, Brazil from July-December 2020.
- 21 Methods
- Starting with initially identified sources of error, we conducted a revised statistical analysis of 22 available data, including data made available with the original papers and public data from 23 the Brazil Ministry of Health. We identified additional uncorrected sources of bias and errors 24 from the original analysis, including incorrect subject exclusion and missing subjects, analysis 25 of longitudinal data with cross-sectional design, an enrolment time bias, and multiple sources 26 of immortal time bias. In models assuming no actual effect from ivermectin use, we 27 conducted Monte Carlo simulations to estimate the contribution of these biases to any 28 observed effect. 29 Results 30
- ³¹ Untreated statistical artefacts and methodological errors alone lead to dramatic apparent
- ³² risk reduction associated with ivermectin use in both studies. The magnitude of apparent risk
- reduction from these artefacts is comparable to the results reported by the studies
 themselves, including apparent protection from infection, hospitalisation, and death, and
- ³⁵ including the reported apparent dose-response relationship.

36 Conclusions

41

- ³⁷ The inference of ivermectin effect reported in both papers is unsupported, as the observed
- ³⁸ effects are entirely explained by untreated statistical artefacts and methodological errors.
- ³⁹ Our re-analysis calls for caution in interpreting highly publicised observational studies and
- ⁴⁰ highlights the importance of common sources of bias in clinical research.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Introduction 42

- The first half of 2020 was marked by both the beginning of the COVID-19 pandemic and frantic 43
- efforts around the globe to prevent and contain its spread. Most of those initial efforts relied 44
- on non-pharmaceutical interventions (e.g., social distancing, masks, travel restrictions, and re-45
- gional lockdowns) to "flatten the curve" and reduce the strain on healthcare systems before 46
- effective treatments and vaccines became available [1, 2]. As the pandemic unfolded, health-47 care systems worldwide rapidly became overburdened with an increasing number of severely
- 48 ill patients and high COVID-19 mortality rates. 49
- In Brazil, there was immense interest in early COVID-19 treatment during the initial phase 50 of the pandemic, including the potential use of the anti-parasitic drug ivermectin [3]. While 51
- there was no clinical evidence of ivermectin efficacy for COVID-19, initial in vitro studies at the
- 52 time had shown potential antiviral activity of ivermectin in cell culture [4], which fuelled interest 53
- in its use. Starting in July 2020, the city of Itajaí (in the southern Brazil state of Santa Catarina) 54
- [5, 6] implemented a controversial city-wide program in July 2020 as a potential COVID-19 pro-55
- phylaxis. Eligible residents were offered ivermectin pills with an intermittent dosing schedule 56
- of 0.2 mg/kg of body weight (up to a maximum 24 mg for those above 90 kg body weight) each 57
- day for two consecutive days, repeated every 15 days. 58
- In two closely related retrospective analysis studies of the Itajaí program, Kerr, Cadegiani 59 et al. [7, hereafter KC22] and Kerr, Baldi et al. [8, hereafter KB22] made dramatic claims of ivermectin benefit. KC22 concluded that using ivermectin in the Itajaí program resulted in a 44% 61 reduction in COVID-19 infections. Among all infected individuals, KC22 reported 37% reduction 62 in hospitalisation and 43% reduction in mortality associated with ivermectin use. These already 63 dramatic results were even larger after the application of propensity score matching (PSM) and 64 adjustment for other covariates. Furthermore, KB22 presented an even more startling dose-65 dependent benefit among infected individuals: the so-called "strictly regular" ivermectin users 66 experienced a 92% reduction in mortality compared to non-users and an 82% reduction com-67
- pared to irregular users. 68 These two papers gained significant public attention and contributed to ongoing public 69 policy debates, both about COVID-19 treatment and prevention, and about trust in the medical 70 and scientific establishment. Each paper has an Altmetric score in the top five per cent of *all* 71 scientific research, has been the subject of news reporting, and has been shared on social 72
- media or viewed at the journal site hundreds of thousands of times. KC22 and KB22 have also 73
- attracted the attention of fact-checkers, but published critiques to date have mostly focused 74
- either on the limits of observational studies in general or on missing covariates and superficial 75
- peer review of these papers specifically [9–11]. In response, the Editor in Chief of Cureus has 76 77
 - defended the peer review process and subsequent publication of these studies [12].
- Given the widespread dissemination and discussion of these papers, it is crucial to pro-78 vide an unbiased critique to foster a more informed public debate on scientific and medical 79
- research, ultimately helping to protect the public from scientific misinformation [13, 14]. This 80
- unbiased critique is particularly significant for influential papers addressing polarising topics 81
- of public interest, such as the use of ivermectin as a treatment for COVID-19 [15]. 82
- In this work, we take a direct approach by reanalysing the data available from KC22 and 83 KB22 and combining it with public data from the Brazilian Health Ministry. We identify a va-84
- riety of important statistical fallacies and other errors, and use simulations to estimate the 85
- consequences of leaving these issues untreated. Our analysis demonstrates that the seem-86
- ingly dramatic benefits of prophylactic ivermectin for COVID-19, as reported in both KC22 and 87
- KB22, can be entirely attributed to unresolved statistical fallacies present in the original analy-88
- ses. The code for all analyses presented in this manuscript can be found on GitHub, ensuring 89
- the reproducibility of our findings. 90
- Results 91

The data from KC22 and KB22 92

- The analyses of KC22 and KB22 compared events (infections, hospitalisations, and deaths) be-93
- tween participants in the program (who volunteered to take ivermectin as a prophylactic agent) 94

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

- and non-participants within a fixed study period (from July 7 through December 2, 2020). KC22
- described the data set as *excluding* individuals who tested positive from the registry data prior
 to July 7, 2020.

KC22 combined two data sets: one of the participants in the ivermectin prophylaxis pro-

99 gram and the other from a citywide population registry to retrieve non-participants' data. As

we received no response about the availability of original data sets after contacting both the

city authorities in Itajaí and the authors of KC22 and KB22, we restricted our analysis to KC22 supplementary data on OSF posted with KC22 by the corresponding author Flavio Cadegiani

and official public data from the Brazil Ministry of Health.

KC22 claimed virtually no missing values in the data because of mandatory reporting and indeed, most fields for each individual record were completely filled in. However, crucial information was missing for *all* participants in the data. For example, the amount of medicine for an individual was a function of weight (≤ 0.2 mg ivermectin/kg body weight/day for two days every 15 days), but neither body weight nor dosage category were reported. The KC22 data also failed to include any dates other than the date of birth; dates of program enrolment, med-

ication collection, infection, hospitalisation, or death were all missing.

Data entry errors in KC22 data were not uncommon. For example, while the maximum possible total ivermectin usage over the study period was 80 tablets, hundreds of users were recorded as having more than 80, and in some cases thousands, of tablets.

KC22 mistakenly included prior infections and hospitalisations, primarily in the

115 non-user group

The authors describe the data as representing "all events" of COVID-19 infection, hospitalisa-116 tion (in public hospitals), and deaths within the study period (7 July and 2 December 2020). The 117 dates of these events, however, were neither used in the original analysis nor contained in the 118 supplementary data. Fortunately, official public data from the Brazilian Health Ministry's Uni-119 fied Health System (DATASUS) provides detailed information for hospitalisations and deaths 120 of COVID-19 patients across Brazil, including event dates. To understand the distribution of 121 events in the KC22 data, we matched city-level Itajaí data with records from the KC22 data 122 based on the date of birth, sex, and 2020 COVID-19 hospitalisation and death. 123

The majority of recorded deaths and hospitalisations in KC22 were matched to DATASUS 124 data (132/141 deaths, 94%, and 43/93 hospitalised survivors, 46%). To our surprise, COVID-19 125 symptom onset occurred before July 7, 2020 in 45 of the matched individuals, and 87% of those 126 (39/45) were classified as non-users in the KC22 analysis (Table 1A, p < 0.001 for association 127 between exposure group and mistaken inclusion). When we looked at subgroups by mortality 128 for those individuals, the bias for mistaken inclusion of early infections in the non-user group 129 was more severe for those who died (31 non-users, 2 users, 94% non-user, p < 0.001) than for 130 those who survived (8 non-users, 3 users, 73% non-user, p = 0.088Table 1B). 131

Because the DATASUS records during the study period are primarily hospitalisations and deaths, we do not currently have strong direct evidence that the biased inclusion of pre-study infections in the non-participant group extends to non-hospitalised subjects. However, the mistaken pre-study enrolment of non-users accounted for 40% of matched non-users, and all infected non-users were included in the propensity score matching of KC22, so the impact of this mistake along was dramatic

137 this mistake alone was dramatic.

KC22 data was biased towards a subset of early infections

KC22 and KB22 under-reported deaths and severely under-reported hospitalisations from COVID-19 in Itajaí. While KC22 reports 141 deaths, DATASUS records 186 adult COVID-19 deaths among Itajaí residents during the study period, and 183 reported deaths following symptom onset in the same period, 30% higher than in KC22. KC22 reported 185 total hospitalisations from a study population of 159,560 (0.12% hospitalised); official government data reports 651 Itajaí resident adult hospitalisations for COVID-19 from infections in the second half of 2020, of whom 479 had symptom onset during the KC22 study period (a hospitalisation rate 259% greater than that reported in KC22).

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

A: All uniquely mapped hospitalised KC22 study subjects, unstratified.

	non-user ¹	IVM user ¹	p-value ²
All Brazilian Health Ministry-mapped individuals (178 total)			<0.001
Covid onset on or after 7 July 2020	58 (60%)	72 (92%)	
Covid onset before 7 July 2020	39 (40%)	6 (7.7%)	
¹ n (%)			

²Fisher's exact test

B: Subgroup analysis of uniquely mapped KC22 hospitalised study subjects, stratified by Covid-19 death outcome.

	non-user ¹	IVM user ¹	p-value ²
Alive (43)			0.088
Covid onset on or after 7 July 2020	13 (62%)	19 (86%)	
Covid onset before 7 July 2020	8 (38%)	3 (14%)	
Dead (135)			<0.001
Covid onset on or after 7 July 2020	46 (60%)	56 (97%)	
Covid onset before 7 July 2020	31 (40%)	2 (3.4%)	

¹n (%)

²Fisher's exact test

Table 1. Mistaken inclusion of pre-study infections in the non-user group. KC22 study participants uniquely mapped with Brazil Health Ministry (SUS) individuals as described in the text. Parts (a) and (b) show overall and subgroup analysis, respectively.

The death/hospitalisation ratio was also much higher for KC22 (141/185, 76.1%) than for Itajaí as a whole (183/479, 38.5%). KC22 included only hospitalisations in public hospitals, which may partially account for the difference among hospitalised survivors and death/hospitalisation ratio but raises fundamental unaddressed issues of confounding. The under-reporting of hospitalisations and deaths cannot be attributed to the reported ivermectin effects claimed by KC22.

To further understand this issue, we compared the dates of COVID-19 symptom onset, hospitalisation, and death for the 175 records mapped between KC22 and DATASUS (Fig. 1A, top). Dates of death were almost entirely contained within the study period, consistent with KC22's claim to have analysed events during this period. The same is true of hospitalisation dates for hospitalised survivors. However, dates of hospitalisation for matched deaths (Fig. 1A, middle) and dates of symptom onset for both hospitalisations and deaths (Fig. 1A, bottom) occurred well before the beginning of the study period.

Strikingly, the KC22 data not only mistakenly included hospitalisations and deaths with symptom onset *before* the study period, but almost all of the remaining matched hospitalised individuals experienced symptom onset in the first half of the study period (Fig. 1A, bottom). KC22 thus almost entirely neglected the second wave of COVID hospitalisations, which peaked at the end of the study period (Fig. 1B). Indeed, symptom onset among the *uncounted* deaths primarily occurred at the tail end of the study period, when the December 2020 wave was getting under way (Fig. S1).

The KC22 analysis appears to treat the data as cross-sectional, analysing (as described in 167 KC22) "all events as they occurred during the citywide governmental COVID-19 prevention with 168 ivermectin program, from July 7, 2020, to December 2, 2020". In reality, the data is inherently 169 longitudinal: hospitalisations precede deaths and infections precede hospitalisations. Includ-170 ing all deaths within a fixed time period, as described in KC22, would lead to mistaken inclusion 171 of prior hospitalisations and infections (as seen in Fig. 1A); including all hospitalisations would 172 have inevitably included prior infections. The opposite problem would appear near the end 173 of the study period, where hospitalisations and deaths would be excluded from analysis even 174 if the infections that preceded them occurred during the study period. This is exactly what is 175 observed (see Fig. S1), in addition to the under-counting of events late within the study period. 176

perpetuity. It is made available under a CC-BY-ND 4.0 International license .




Figure 1. Symptom onset and study group allocation. A. Event dates for 132 matched Covid deaths and 43 matched hospitalised survivors mapped to the SUS data from KC22. The three sub-panels show recorded dates of death, hospitalisation, and symptom onset. B. Official Brazilian Health Ministry entries for records of death or hospitalisation among adult residents of Itajaí. C. The probability of an individual considered in the study being allocated to the non-user group changes dramatically over time during the allocation of participants in KC22. Enrolment was estimated using data from contemporaneous Itajaí municipal bulletins and news reporting. See Methods for details.

177 Enrolment to the ivermectin program continued during the study period

Both KC22 and KB22 compared events between adult residents of Itaiaí who did or did not 178 participate in the ivermectin program over the entire study period. KC22 claimed "[t]his strict 179 interval avoids differences in terms of periods of exposure". This cannot be true, however, as 180 not all 113,845 participants started exactly on July 7, 2020. Consider an individual who reported 181 symptoms on July 8, but had not yet joined the ivermectin distribution program. That individ-182 ual would be ineligible for inclusion in the KC22 study as an ivermectin user, but would instead 183 be treated in the analysis of KC22 as an infected non-user. The biased allocation of new infec-184 tions into the non-user group (Fig. 1C) would continue for as long as the distribution program 185 enrolled new participants. This alone is a classic case of immortal time bias [16], but because 186 the most rapid enrolment occurred during the peak infection period in July 2020 (Fig. 1B), it 187 also coincides with substantial chronological bias [17]. We describe the immortal time bias 188 and chronological bias during enrolment collectively as "enrolment bias" to distinguish these 189 two sources of bias from other sources of bias described later. 190

Enrolment bias, incorrect inclusion of already infected participants, and biased
 sampling led to large apparent protection against infection, hospitalisation,

¹⁹³ and death in KC22

¹⁹⁴ We estimated the effects of the issues above using Monte Carlo simulation. We simulated the

- 195 KC22 study under a model of no actual ivermectin effect but successively including enrolment
- ¹⁹⁶ bias, the incorrect inclusion of subjects with symptomatic onset prior to the study, and the
- empirically biased sampling towards the beginning of the study. We simulated symptom onset

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

in individual patient data cohorts each the size of the data set in KC22. To simulate the dates of 198 symptom onset, we used daily Itajaí notifications of infection from the Brazil Health Ministry. To 199 simulate enrolment over time, we used contemporaneous local municipal bulletins and news 200 reports of program enrolment and assumed participants began taking ivermectin immediately. 201 We developed multiple models to estimate the individual and cumulative effects of the 202 identified biases and errors. Each model used the numbers reported in KC22:7231 infections 203 within a cohort of 159,560 individuals (infection rate of approximately 4.5%). Additionally, we 204 simulated hospitalisations and deaths to match KC22 totals, using dates sampled from the 205 Brazil Health Ministry records, as detailed in the Methods and Materials section. Results are 206 reported based on 1000 simulations of each model and compared to reported values from 207 KC22. Hospitalisations and deaths reported among infected individuals and compared to the 208 infected individuals from KC22 prior to propensity score matching. 209 The enrolment bias present in KC22 leads to an estimated fictitious risk reduction for infec-210

tion of 17% for users of an ineffective medicine. This result stems from our first model (i-ENR), in which we randomly sampled infections from the distribution of onset dates between July 7 and December 2, 2020. In addition to the enrolment bias, the incorrect inclusion of subjects with symptomatic onset prior to the study period leads to an additional 10% fictitious risk reduction for infection. In our second model (i-INF), we simulated incorrect inclusion by sampling from symptom onset dates where the notification date was between July 7 and December 2, 2020. The i-INF model thus encompassed both enrolment bias and the mistaken inclusion of

218 early infections.

Lastly, an additional 24% fictitious risk reduction for infection is caused by the biased sam-

		Sin	nulation		Literature
	i-NEG	i-ENR	i-INF	i-KC22	KC22 [7]
has enrolment bias		~	~	~	✓
includes prior infections			~	~	✓
has missing data				~	~
Infection					
Rate (non-user)	4.53%	5.14%	5.62%	7.15%	6.64%
Rate (user)	4.53%	4.29%	4.10%	3.48%	3.69%
Risk ratio		0.834	0.729	0.487	0.555
95% CI		[0.80-0.88]	[0.70–0.76]	[0.47-0.51]	[0.53-0.58]
p		<0.001	<0.001	<0.001	<0.001
Risk reduction		17%	27%	51%	44%
Hospitalisation					
Rate (non-user)	0.12%	0.14%	0.16%	0.20%	0.22%
Rate (user)	0.12%	0.11%	0.09%	0.08%	0.08%
Risk ratio		0.750	0.588	0.398	0.349
95% CI		[0.56–1.03]	[0.44-0.80]	[0.28-0.56]	[0.26-0.47]
p		0.039	<0.001	<0.001	<0.001
Risk reduction		25%	41%	60%	65%
Death					
Rate (non-user)	0.09%	0.11%	0.13%	0.17%	0.17%
Rate (user)	0.09%	0.08%	0.07%	0.06%	0.05%
Risk ratio		0.707	0.541	0.335	0.315
95% CI		[0.50–1.02]	[0.39–0.77]	[0.25-0.47]	[0.22-0.43]
p		0.026	0.002	<0.001	<0.001
Risk reduction		29%	46%	66%	68%

Table 2. Apparent protection provided by biases and errors in KC22. Apparent protection against infection, hospitalisation, and death due to enrolment bias, mistaken inclusion of prior infections, and missing data. Comparisons are between users and non-users, as defined in KC22. Three different simulation strategies were used to simulate the isolated effects of biases identified in [7] along with a negative control (i-NEG). i-KC22 and the published KC22 data set include all three biases. Simulations are as described in the text.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

pling towards the beginning of study observed in KC22. In the third model family (i-KC22), we
 simulated the sampling bias in Fig. 1B by sampling infections using the distribution of infection
 dates of matched individuals. Details are discussed in the methods section. The i-KC22 model
 family most closely matched the errors and biases so far discussed in KC22.

The results of the models, alongside the published results of KC22 and a trivial negative model (i-NEG, with neither ivermectin effect nor any biases) are shown in Table 2. Each source of bias reduced the apparent incident rates of infection, hospitalisation, and death of ivermectin users and, hence, increased the apparent risk reduction of the exposure. Biases in the design and execution of KC22 account for virtually all of the reported protection attributed to ivermectin.

The estimated effect of enrolment bias in the i-ENR model is conservative, since we as-230 sumed optimistically that news reporting was accurate and that ivermectin use began imme-231 diately for all participants. In addition, we did not include uncertainty in the model parame-232 ters, so confidence intervals are likely under-estimated. While we have direct evidence for the 233 temporal-biased sampling in the case of hospitalisation and death, the effect of temporal sam-234 pling bias for infections in i-KC22 is indirectly estimated based on assumed consistency with 235 hospitalisations and deaths. Full details of the simulation methods are found in the Methods 236 and in the GitHub repository accompanying this paper. 237

²³⁸ KC22 hospitalisation and mortality results introduced attrition bias by design

COVID-19 outcome events occur in sequence: hospitalisation usually precedes COVID-19 239 death; COVID-19 symptom onset always precedes COVID-19 hospitalisation and COVID-19 240 death. KC22 stated they had included "all events" from July 7-December 2, 2020, so hospi-241 talisations and deaths *after* the study period following symptom onset *during* the study period 242 were ignored. The enrolment bias described above thus leads not just to a fictitious protection 243 against infection, but to differences between exposure groups in the distribution of infections 244 over time: non-user infections accumulate earlier in the study period, and infections among 245 users accumulate later. Indeed, the median symptom onset date for the non-user group over 246 1000 simulations of i-ENR was September 4, 2020, while that for the user group was October 2, 247 almost a month later. The temporal difference in symptom onset leads to additional bias for 248 later hospitalisations and deaths due to attrition [18, 19]. 249

Attrition from events after the study period can occur in both exposure groups. We es-250 timated attrition rate from failure to count post-study events in each exposure group in all 251 simulation models, and calculated a risk ratio for hospitalisation and death within each group 252 by comparing the case without attrition (no cutoff for event counting) to the case with attrition 253 (events after December 2, 2020 not counted). As shown in Table 3, attrition bias provides ap-254 parent (though fictitious) protection against hospitalisation and death in all cohorts, and in all 255 cases the fictitious protection is greater in the user group than the non-user group. Adding 256 the possibility of pre-study inclusion in the i-INF model (Table 3B) lowers the protection in the 257 non-user group when compared to the enrolment-bias only i-ENR model. Attrition bias in the 258 i-KC22 model was estimated by including unmatched late deaths (Fig. S1) in the model. 259

Fig. 2 illustrates the basis of this finding in detail. In KC22, infections tended to occur earlier 260 in the non-user group because of the delayed enrolment in the user group and the July 2020 261 infection peak (Fig. 2A). Death events after the follow-up period are lost to attrition as a rule in 262 any given cohort, but this attrition is more likely among users than non-users in KC22, as shown 263 for a single simulated cohort in Fig. 2B. A higher percentage of deaths than hospitalisations 264 are lost to attrition in both groups (Fig. 2C) but the ivermectin user group is more likely to 265 have uncounted hospitalisations and deaths than the non-user group. This translates to an 266 increased risk of attrition in the ivermectin group, a relative risk that is higher for deaths than 267 for hospitalisations (Fig. 2D) Note that the protection shown in Fig. 2D is relative protection of 268 users compared to non-users, as opposed to the apparent protection provided from attrition 269 within each group shown in Table 3. Attrition bias for the i-INF and i-KC22 models are shown 270 in Figs. S2 and S3, respectively. 271

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

A: i-ENR model (1000 simulations)

	outcome	Risk Ratio	95% CI	р	rate of lost events
non-user	hospitalisation	0.94	0.88-0.99	0.120	6%
user	hospitalisation	0.92	0.87-0.97	0.002	8%
non-user	death	0.80	0.70-0.90	<0.001	20%
user	death	0.74	0.66-0.81	<0.001	26%

B: i-INF model (1000 simulations)

	outcome	Risk Ratio	95% CI	р	rate of lost events
non-user	hospitalisation	0.95	0.91-1.00	0.154	5%
user	hospitalisation	0.92	0.87-0.97	0.003	8%
non-user	death	0.84	0.75-0.93	<0.001	16%
user	death	0.74	0.65-0.82	<0.001	26%

C: i-KC22 model (1000 simulations)

	outcome	Risk Ratio	95% CI	р	rate of lost events
non-user	hospitalisation	0.93	0.87-0.99	0.051	7%
user	hospitalisation	0.84	0.76-0.92	<0.001	16%
non-user	death	0.84	0.77-0.91	<0.001	16%
user	death	0.64	0.55-0.73	<0.001	36%

Table 3. Attrition bias provides apparent protection against hospitalisation and death in all cohort. Risk ratios indicate apparent protection from adverse outcomes by loss of events occurring after the study period. Note that the apparent protection in all models is greater for death than for hospitalisation, and greater in the user group than in the non-user group.

The "regular ivermectin user" distinction in KB22 created additional immortal time bias

We now turn to the second paper from the Itajaí study (KB22), which considered the "regular 274 use" of ivermectin. Because actual ivermectin use was not measured. KB22 treated the re-275 turn to collect medication over time as a surrogate measure for the actual ivermectin intake. 276 KB22 further subdivided ivermectin users into exposure groups based on the total amount of 277 medication distributed: regular users (those who had received at least thirty 6 mg ivermectin 278 tablets, or 180 mg total), irregular users (those who had received no more than 10 tablets), and 279 non-users. According to KC22, newly diagnosed COVID-19 patients were recommended "not 280 to use ivermectin" and that "The city did not provide or support any specific pharmacological 281 outpatient treatment for subjects infected with COVID-19". The citywide ivermectin program 282 was, as KC22 and KB22 made clear, the use of ivermectin as a prophylactic for COVID-19, not 283 as a treatment. 284

The central claim of KB22 was a dose-response relationship between ivermectin use and protection from infection, hospitalisation, and death. The exposure groups in KB22, however, were assigned retrospectively based on the amount of medication distributed over time. Moreover, both the language of KC22 and contemporary news reports suggest that users would have stopped ivermectin use upon infection, but the analysis of KB22 assumes the opposite, treating ivermectin usage as an independent variable.

How long would someone have to take ivermectin to be classified as a regular user in KB22? The maximum dosage in the Itajaí program was 4 tablets a day for two days, or 8 tablets every 15 days from day 2 of usage. This would require a minimum of 46 days after enrolment to be classified as a regular user. The more typical 3-tablet dosage would require 61 days. This entire time period is "immortal" time for regular users who stopped ivermectin use upon infection: infections during that time period would result in their allocation to other groups and an apparent reduction of the infection rate in regular users. medRxiv preprint doi: https://doi.org/10.1101/2023.08.10.23293924; this version posted October 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .




Figure 2. Attrition bias in hospitalisations and deaths in KC22 stemmed from enrolment bias. Results are shown for the iENR simulation model; A. Empirical distributions of simulated infection dates over 1000 runs of the i-ENR model. Note the delayed early peak of infections in the ivermectin user group. B. Example from one typical simulation of uncounted deaths among ivermectin users. Each line segment represents an individual in the simulation who was infected and later died, with infection and death dates at the end points. The study end date is marked with a vertical line. C. Hospitalisations and deaths are lost to attrition more frequently in the user group (1000 simulations of the i-ENR model). D. The ivermectin user group has apparent (but fictitious) protection from hospitalisation and death compared to non-users because hospitalisations and deaths are more likely to occur after the end of the study period for the user group. (Results under the other models are shown in Figures S2-S3.)


We simulated the effects of these biases by randomly allocating intended usage among iver-298 mectin users using the total tablet distribution from KC22 data, and truncating to simulated 200 actual usage based on how long an individual participated in the study without infection. We 300 assumed a body weight between 60-90 kg, so 3 tablets per day of use. Because actual changes 301 in usage upon infection are unknown, we considered two distinct scenarios. In the determinis-302 tic scenario, all infected users stopped ivermectin upon infection. In the probabilistic scenario, 303 we used the regularity groupings of KB22 as a proxy for commitment: regular users receiving 304 \geq 30 tablets would stop on infection with a probability of 5%, irregular users would stop with a 305 probability of 30%. As there is no evidence that ivermectin was offered to COVID-19 inpatients 306 at the time, all users would stop taking ivermectin on hospitalisation. 307 The immortal time bias provided by the "regular user" definition in KB22 leads to a strong 308

fictitious dose-response relationship under the assumption of ineffective medicine (Figures 3, 309 S4, and S5.) In the deterministic stopping scenario the dose-response relationship was even 310 stronger than reported in KB22. In the probabilistic setting, which models a very small change 311 in user behaviour upon infection, our simulations closely match the dose-response relation-312 ship found in KB22 (see Table 4). 313

medRxiv preprint doi: https://doi.org/10.1101/2023.08.10.23293924; this version posted October 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

95% Cl Risk Red. p.val RR 95% Cl Risk Red. 0.47-0.51 51% <0.001 0.56 0.53-0.58 44% 0.60-0.68 36% <0.001 0.56 0.53-0.57 49% 0.51-0.67 41% <0.001 0.51 0.45-0.57 49% 0.51-0.67 41% <0.001 0.51 0.45-0.57 49% 0.51-0.67 41% <0.001 0.51 0.45-0.57 49% 0.51-0.67 41% <0.001 0.51 0.45-0.57 49% 0.51-0.67 41% <0.001 0.75 0.66-0.85 25% 0.249-0.74 48% <0.0101 0.00 0.00-0.00 100% 0.01-0.29 85% <0.01 0.00 0.00-0.00 100% 0.01-0.26 79% <0.01 0.00 0.00-0.00 100% 0.01-0.23 33% 0.01 0.31 0.31 0.31-0.74 51% <t< th=""><th></th><th></th><th>Simu</th><th>Simulation</th><th></th><th></th><th>KB2:</th><th>KB22/KC22</th><th></th><th></th><th>Corr,</th><th>'Corrected'</th><th></th></t<>			Simu	Simulation			KB2:	KB22/KC22			Corr,	'Corrected'	
	Summary statistics	RR	95% CI	Risk Red.	p.val	RR	95% CI	Risk Red.	p.val	RR	95% CI	Risk Red.	p.val
	Infection												
	non-user vs user	0.49	0.47-0.51	51%	<0.001	0.56	0.53-0.58	44%	<0.001	1.14	1.07-1.22	-14%	1.000
	non-user vs irregular	0.64	0.60-0.68	36%	<0.001	0.68	0.64-0.73	32%	<0.001	1.07	0.98-1.16	-7%	0.987
	non-user vs regular	0.37	0.33-0.43	63%	<0.001	0.51	0.45-0.57	49%	<0.001	1.38	1.15-1.65	-38%	1.000
	irregular vs regular	0.59	0.51-0.67	41%	<0.001	0.75	0.66-0.85	25%	<0.001	1.29	1.07-1.55	-29%	0.999
	Hospitalisation												
	non-user vs user	0.40	0.28-0.56	60%	<0.001	0.35	0.26-0.47	65%	<0.001	0.93	0.58-1.41	7%	0.294
	non-user vs irregular	0.74	0.49-1.09	26%	0.045	0.52	0.34-0.74	48%	<0.001	0.76	0.42-1.27	24%	0.073
<u> </u>	non-user vs regular	0.15	0.01-0.39	85%	<0.001	0.00	0.00-00.00	100%	<0.001	NaN	NaN	NaN	ΝA
Ľ.	irregular vs regular	0.21	0.01-0.56	%62	<0.001	0.00	0.00-0.00	100%	<0.001	NaN	NaN	NaN	NA
<u> </u>	Death												
<u> </u>	non-user vs user	0.34	0.24-0.47	66%	<0.001	0.32	0.22-0.44	68%	<0.001	1.00	0.60-1.56	%0	0.457
	non-user vs irregular	0.67	0.45-0.98	33%	0.018	0.49	0.31-0.74	51%	<0.001	0.80	0.42-1.37	20%	0.113
	non-user vs regular	0.08	0.00-0.23	92%	<0.001	0.14	0.00-0.38	86%	<0.001	Inf	Inf-Inf	-Inf%	1.000
Table 4. i-KC22 model with probabilistic stop on infection. Stop probability: 0.05 (regular). Statistics for hospitalisations and deaths are reported for all i	irregular vs regular	0.13	0.00-0.37	87%	<0.001	0.28	0.00-0.79	72%	0.070	Inf	Inf-Inf	-Inf%	1.000
0.05 (regular). Statistics for hospitalisations and deaths are reported for all in		Table 4	 i-KC22 mc 	odel with pr	obabilisti	c stop c	on infection	. Stop prob	ability: 0.	30 (irre)	gular),		
		0.05 (re	egular). Stat	istics for ho	spitalisat	ions an	nd deaths ar	e reported	for all inc	lividual	s in the		
CONOR.		cohort.											

perpetuity. It is made available under a CC-BY-ND 4.0 International license .



Immortal time bias protection of infected 'regular' users

Figure 3. KB22's "regular" use group [8] created more immortal time bias. A. Simulated dates of hospitalisation in i-ENR for individuals grouped by exposure according to KB22-defined usage groups. The study end date is marked with a vertical line. B. Dates of death. C. Relative risk of hospitalisation and death for "regular" ivermectin users compared to "irregular" and non-users. Risk ratios are calculated and plotted for each of 1000 simulations. Dates of hospitalisation and death are shown for all individuals across 1000 simulations. (Corresponding results under the i-INF and i-KC22 models are shown in Figures S4 and S5, respectively.)

314 Discussion

Re-analysis of KC22 and KB22 shows no benefit from ivermectin use on infec tions, hospitalisations, or death

- A comparison between the key findings in KC22 and KB22 and our re-analysis is found in Ta-
- ³¹⁸ ble 4. The apparent risk reduction from documented artefacts including well-known biases
- and sampling errors accounts for all of the reported benefits of ivermectin claimed in both
- ³²⁰ KC22 and KB22. As the key findings from Table 4 underlie all subsequent analyses in KC22 and
- ³²¹ KB22, none of the results reported in either paper holds up to scrutiny.

The errors in KC22 and KB22 are pervasive. Should they have been obvious?

The biases and failings in KC22 and KB22 originate from a mix of sources, as outlined in Fig. 4. However, all of the issues except for missing data late in the study period (Fig. 4G) are a consequence of the study design itself. In addition, all of the issues with the possible exception of excluding private hospitalisations (Fig. 4H) lead to fictitious benefit to the ivermectin user group.

While each issue can be considered independently, it is important to note that many of them also interact. For instance, excluding late hospitalisations and deaths (Fig. 4E-F) does not on its own benefit the ivermectin user group, but enrolment bias (Fig. 4A-B) shifts the distribution of non-user infections earlier than user infections, so attrition bias from late events (Fig. 4E-F) provides more apparent protection to users than non-users against hospitalisation and death. All of these biases should be evident, immediately or after some thought, to any scientific or medical professional with training and experience in clinical study design.

Understanding other sources of bias in KC22 and KB22 requires data. To appreciate the chronological bias during enrolment, for example, one must at least be aware of public data such as reported case rates over time. Still other issues, such as potential missing data, require careful examination, cross-tabulation, and analysis of available data to identify the extent of particular issues.

Another striking bias in KC22 and KB22, not addressed by our analysis, is the complete lack of attention to health inequity. This is hard to fathom given the likelihood of socioeconomic medRxiv preprint doi: https://doi.org/10.1101/2023.08.10.23293924; this version posted October 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.






Figure 4. Schematic overview of different biases and errors in the design and analysis of KC22 and KB22. Red icons represent mistaken inclusion of events; gray icons represent missing, dropped, or wrongly excluded events. A-H. Biases and errors in KC22. I Additional biases and errors in KB22 (which also includes all issues in KC22).

differences between participants and non-participants. Participation in the Itajaí program re-342 quired individuals to take proactive steps: they needed to travel to distribution centres, sign 343 up for the program, register their information, receive medication, and return periodically for 344 medication refills. KC22 and KB22 included known prognostic factors in propensity score match-345 ing after infection. However, neither KC22 nor KB22 accounted for any socioeconomic factors 346 as potential covariates affecting either infection risk or prognosis, even though impoverished 347 and vulnerable populations are known to have higher risk and worse outcomes for many dis-348 eases and to be harder to reach and recruit for clinical studies [20, 21]. These well-known 349 inequities were magnified during the early phases of COVID-19 because of stresses in public 350 health systems [22–25]. Furthermore, health inequity — including during the COVID-19 pan-351 demic — is an area of active study in Brazil, with greater risk of hospitalisation and death from 352 social inequity and disadvantage [26–28]. Indeed, health inequity is an unavoidable concern 353 for these study if for no other reason than the fact that hospitalisations are only reported for 354 public hospitals (Fig. 4H). 355 In our view, the issues above should have been recognised and addressed by the authors, 356 and most of them should have been recognised and questioned by the reviewers. 357 They were not. Instead, each paper was submitted, revised, and accepted in a matter of 358 days, and immediately entered public discussion with a primary focus on the large size of the 359 study population and the large magnitude of reported risk reduction, as if a large reported 360 risk reduction must be true if the study itself is large. Unfortunately the opposite may hold if a 361

study is built on a fallacious design. In such a case both the reported treatment effect and the 362 apparent confidence (especially when reported as "statistical significance") may increase with 363

a larger study population [29-31], even if there is no actual effect of treatment. This appears 364

to be the situation with KC22 and KB22. 365

medRxiv preprint doi: https://doi.org/10.1101/2023.08.10.23293924; this version posted October 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

The growing consensus and persistent divide on use of ivermectin for Covid-19 366

lvermectin has been known to have different mechanisms in vertebrates and nematodes for 367 over 30 years [32]. Ivermectin's mechanism and safety as an antiparasitic stems from its potent 368 targeting of glutamate-gated chloride channel receptors essential for nematodes but not found 369 in vertebrates [33]. When ivermectin was first suggested for COVID-19 based on *in vitro* exper-370 iments [4], the suggestion was not altogether unreasonable; some of the same researchers 371 had reported a possible antiviral mechanism through the nuclear $\alpha/\beta1$ importin complex[34. 372 35]. However, those studies were undertaken in cell lines such as Vero E6 or HeLa (both widely 373 used for viral assays); when careful comparison studies were carried out in more relevant hu-374 man bronchial epithelial cells, ivermectin had no effect on SARS-CoV-2 replication [36]. There 375 were other reasons to be sceptical of the initial enthusiasm; the well-studied pharmacokinetics 376 and pharmacodynamics of ivermectin strongly imply that it would be impossible to replicate 377 in humans the concentrations required for *in vitro* activity [37, 38]. 378

Some doctors began prescribing ivermectin based on preliminary and preclinical studies, 379 even as most mainstream public health authorities encouraged waiting for clinical trials. As a 380 result, hundreds of studies of ivermectin for COVID-19 have been published in the last three 381 years, including dozens of clinical trials, numerous cell biology and biochemical studies, mech-382 anistic speculation based on molecular docking, and competing reviews. Some of the earli-383 est high-profile studies reporting large effects of ivermectin have been retracted or otherwise 384 flagged for ethical concerns [39, 40]. Meta-analyses that included such flawed analysis have 385 also been retracted [41] and reviews advocating for the immediate use of ivermectin [42] have 386 been criticised as deeply problematic [43]. One possible lesson from both ivermectin meta-387 analysis and vaccine clinical trials is to require use of anonymised individual patient data, rather 388 than summary data alone, for assessment of bias in meta-analysis [44, 45]. 389

Recent rigorous randomised clinical trials have largely not found clinical benefit for iver-390 mectin use in COVID-19 [46–50], strengthening the growing scientific and clinical consensus 391 not to recommend clinical use of ivermectin for COVID-19 treatment or prophylaxis [51]. This 392 consensus remains persistently rejected by ivermectin advocates citing smaller RCTs or obser-393 vational studies that appear to show an enormous effect of ivermectin. As with any area of 394 active research, interpretations regarding ivermectin's efficacy might differ based on the cho-395 sen data sets and their assessments, underscoring the need for more thorough and objective 306 analysis of the available literature. What began as a scientific disagreement has become a 397 challenge for effective science communication in the context of public health. 398

This work focuses on the fallacies in KB22 and KC22 specifically, rather than any general 399 question of ivermectin for COVID-19. Readers interested in that question should refer to [51]. 400 Our work highlights the dangers posed by scientific misinformation. Not only have the un-401 founded conclusions of these papers been used to spread misinformation, methodological crit-402 icism of them leads to aggressive and misleading attacks, as happened upon the initial release 403 of this study as a preprint [52, 53]. Regional, national, and international organisations¹ have 404 sprung up to advocate for ivermectin and other non-proven or weakly supported treatments 405 for COVID-19, and strive to influence public opinion. Ivermectin-for-COVID advocacy groups 406 maintain their position and influence through mechanisms including promoting "science by 407 preprint", exploiting perfunctory peer review, aggressively using social media, and cultivating 408 socio-political alliances including the anti-vaccination movement. Observational studies are 409 particularly vulnerable to misinterpretation and use as misinformation. 410

The use of simulation to solve statistical fallacies 411

Statistical fallacies or 'statistical lies' affect our lives in many ways: we read them in newspapers, 412

- we hear them in conversation, we inadvertently make them ourselves, and they are unfortu-413
- nately common in science. The fallacies often go hand-in-hand with cognitive heuristics that 414
- bias our perception of reality [54]. For instance, salience bias (the tendency to focus on remark-415 able events or prominent features) leads people to overestimate risk of rare events and make 416

¹These include the Front Line COVID-19 Critical Care Alliance (FLCCC) and America's Frontline Doctors in the United States. Médicos Pela Vida in Brazil, and the World Council for Health.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

decisions that appear irrational and incur a cost to themselves and to society [55, 56].

Despite the review process, biases and statistical fallacies also arise in scientific literature [19, 57], and proliferation of these fallacies carries the potential for disaster: the incorrect conclusions of KC22 and KB22 for instance, were used to support arguments that ivermectin was at least as effective as vaccination against COVID-19 related death, potentially increasing vaccine hesitancy and thereby increasing the global death toll due to COVID-19.

One of the most famous statistical fallacies is seen in the Monty Hall problem, named for the 423 original host of the American television show "Let's Make a Deal", where a variant of this puzzle 424 appeared in every episode. In this puzzle, a player is presented three closed doors and asked 425 to choose one. Behind one of these doors is a prize which the player will win if they choose 426 the correct door. Once the player has chosen a door, the host reveals which of the other two 427 doors does not contain the prize, and subsequently asks the player if they would like to stick 428 with their initial choice or switch to the other closed door. When presented for the first time, 420 most people assume that switching their choice will not affect the likelihood of winning a prize 430 [58] The answer, however² is that the likelihood of winning a prize after switching is two thirds, 43 whereas the likelihood of winning is only one third when the participant doesn't switch doors. 432 Remarkably, even when people are shown explanations, simulations and mathematical 433 proofs, many - including renown statisticians - still refuse to accept the answer of the puzzle [58, 434 591. Studies using repeated simulations of the Monte Hall problem show a remarkable adop-435 tion of the correct answer. Herein participants play the game over and over on the computer, 436 and get feedback on how often they won the prize. The Monte Carlo simulation that we use 437 here is basically an automation of this process. Akin to the Monte Hall problem, researchers 438 may falsely reason that it is correct to include participants that got infected by COVID-19 before 439 registering/consuming ivermectin as non-users in a rolling registration context. But simulating 440 the process unveils that an artificial efficacy emerges for the treatment group. We hope there-441 fore that our work extends beyond a correction of these two papers, and helps researchers of 442 observational trials in general not to repeat these fallacies. 443

444 Methods and materials

445 Starting data

We used data made available by the authors of KC22 at DOI 10.17605/OSF.IO/UXHAF. This data 446 was missing critical information, which we addressed as follows. City-wide monthly infections 447 and deaths were taken from [43], which in turn obtained them from the Brazilian Health Min-448 istry. We also used the Brazilian Health Ministry resource to obtain national reporting data 449 for individuals including dates of symptom onset, hospitalisation, and death, though this was 450 largely limited to hospitalised patients during the time of the study. We downloaded this data 451 on 26 September 2022. While the study began enrolling participants on July 7, 2020, the KC22 452 data does not indicate when any individual patient joined the program and was provided iver-453 mectin. We used an estimate of program enrolment over time by following municipal bulletins 454 from Itajaí as well as contemporaneous articles in the local Itajaí press (e.g. [60]). Sources for 45 each estimate are in the GitHub repository. 456

457 Analysis of overlap between KC22 and Brazilian Health Ministry data

Data from KC22 was cross-tabulated with public data from the Brazilian Health Ministry. Af-458 ter identifying variables that were available in both data sets, we identified matches between 450 infected individuals (both users and non-users) from KC22 and infected individuals from the 460 health ministry data. Matches were counted only if they were identical for all of the variables 461 considered (birth date, hospitalisation status, sex, and death outcome). We considered records 462 of deaths and hospitalised survivors separately. When matching on deaths, we ignored hos-463 pitalisation because hospitalisation details were apparently incorrect for many records of de-464 ceased individuals in the KC22 data. Specifically, 95% of death records in the Itajaí citywide 465 ²in the simplest case, assuming that the host always opens the wrong door and always gives the player a choice to

switch

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

data from DATASUS were marked as hospitalised, but only 65% of deaths in the KC22 data were marked as hospitalised.

A few entries in KC22 had more than one match to the health ministry data, which could be due to data errors or multiple infections. We included only the single match with the latest date of symptom onset in order to avoid over-counting pre-study inclusion in KC22 and to minimise the estimate of immortal time bias.

472 Allocation to exposure and outcome groups

For each simulation experiment, repeated Bernoulli trials were conducted for each of the 159,560 individuals to assign them to exposure groups (users or non users) as well as outcomes (infections, hospitalisations, deaths). Hospitalisation was always preceded by infection, and death was always preceded by hospitalisation. All allocation probabilities were fixed based on the number of users, non-users, infections, hospitalisations, and deaths reported in KC22

(e.g. probability to be an ivermectin user is 113,844 / 159,560).

479 Simulation of event times and ivermectin usage

For each simulated individual that contracted COVID-19, was hospitalised, or died, the event 480 date was sampled from the empirical distributions of official government records. In the case 481 of missing data, we used complete cases to confirm published reports that time periods in the 482 progression of COVID-19 were well-approximated by a Weibull distribution [61–63], and then 483 created an objective function using the empirical mean and standard deviation of time delays 484 to numerically optimise the Weibull scale and shape parameters to impute missing event dates. 485 In the i-ENR and i-INF models, the empirical distribution of symptom onset times were used 486 identically, but limited pre-study onset (< 1 month) was possible in the i-INF model provided 487 the notification date was within the study period. In the case of the i-KC22 model, we sampled 488 onset dates for matched records for those marked as hospitalised or deceased. For those not 489 marked as hospitalised or deceased, imputed onset dates from a smooth (loess) distribution 490 of onset dates from the matched records. We included unmatched late (post-study period) 491

⁴⁹² hospitalisations and deaths in order to estimate the impact of these biases in Table 3.

Intended ivermectin usage was truncated to actual usage as follows. In probabilistic truncation, infected users with high intended usage (\geq 30 pills) were less likely (p = 0.05) to stop usage on infection than those with lower intended usage (p = 0.3). In deterministic truncation, all infected users stopped ivermectin use upon infection. In all cases, infected users stopped upon hospitalisation. Ivermectin users where split into irregular (\leq 10 pills) and regular users (>30 pills) based on simulated actual usage.

499 Calculation of simulated estimates

Risk ratios were calculated using unconditional maximum likelihood (Wald statistic), while confidence intervals and p values estimated from 1000 bootstraps using the riskratio.boot function from the epitools package in R [64]. Summary statistics from KC22 and KB22 were reestimated the same way for consistency. For summary statistics after correction, we assumed any true effects of ivermectin were independent of apparent effects from artefacts and errors. Risk ratios, confidence intervals, and p values after correction were calculated by 1000 boot-

⁵⁰⁶ straps of simulated and reported data for each simulation.

Data and code availability

All data is publicly available at either DOI 10.17605/OSF.IO/UXHAF (posted by Kerr et al), the Brazil Ministry of Health (https://www.gov.br/saude/pt-br), or Our World in Data (https://ourworldindata.org/COVID-cases). R code to reproduce the analysis is available at

https://github.com/gtuckerkellogg/itajai-reanalysis.

512 Author contributions

⁵¹³ RM conducted the research required to uncover all fallacies mentioned in the manuscript (de-

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

- ⁵¹⁵ pendently uncovered and estimated the immortal time bias, enrolment bias, and attrition bias.
- 516 RM and GTK wrote the simulation and analysis code. GTK in particular, RM, and ACPA con-
- tributed to writing and reviewing the manuscript. ACPA acquired the data from the Brazilian
- Health Ministry. ACPA has been in frequent contact with Itajaí City Hall in an attempt to get
- access to missing raw data. RM has been in frequent contact with the KC22 and KB22 authors
- $_{\mathtt{520}}$ in an attempt to discuss the issues in their work before publishing this manuscript. RM has
- additionally been in frequent contact with the authors following the initial preprint release,
- attempting to address the incorrect public statements made by the authors of KC22 and KB22.

523 Acknowledgements

- $_{\tt 524}$ $\,$ We thank Gideon Meyerowitz-Katz, Lisa Tucker-Kellogg, Andrew Gelman, Amichai Perlman, and
- Annelot Mills for their valuable comments and feedback. We would like to thank Daniel Victor
- Tausk for identifying issues related to DATASUS filtering in our preprint and for recommending
- ⁵²⁷ more precise methods to match DATASUS with data from KC22.
- **528** References
- [1] Seth Flaxman et al. "Estimating the effects of non-pharmaceutical interventions on
- ⁵³⁰ COVID-19 in Europe". In: *Nature* 584.7820 (Aug. 2020). Number: 7820 Publisher: Nature ⁵³¹ Publishing Group, pp. 257–261.
- Patrick G. T. Walker et al. "The impact of COVID-19 and strategies for mitigation and
 suppression in low- and middle-income countries". In: *Science* 369.6502 (July 24, 2020).
 Publisher: American Association for the Advancement of Science, pp. 413–422.
- [3] Leonardo Furlan and Bruno Caramelli. "The regrettable story of the "Covid Kit" and the
 "Early Treatment of Covid-19" in Brazil". In: *The Lancet Regional Health Americas* 4 (Dec.
 2021), p. 100089.
- ⁵³⁸ [4] Leon Caly et al. "The FDA-approved drug ivermectin inhibits the replication of ⁵³⁹ SARS-CoV-2 in vitro". In: *Antiviral Research* 178 (June 1, 2020), p. 104787.
- [5] Decree 11940 2020 of Itajaí SC. Regulamenta a Distribuição do Medicamento Ivermectina no
 Município de Itajaí. July 7, 2020. URL: https://web.archive.org/web/20221022092413/https:
- //leismunicipais.com.br/a/sc/i/itajai/decreto/2020/1194/11940/decreto-n-11940-2020-
- regulamenta-a-distribuicao-do-medicamento-ivermectina-no-municipio-de-itajai (visited on
 10/22/2022).
- [6] "The Brazilian city being turned into a coronavirus "lab experiment"". In: *Coda Story https://www.codastory.com/waronscience/brazil-covid19-ivermectin/* (Aug. 27, 2020).
- Lucy Kerr et al. "Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective,
 Observational Study of 223,128 Subjects Using Propensity Score Matching". In: *Cureus* 14,1 (Jan. 15, 2022). Publisher: Cureus.
- [8] Lucy Kerr et al. "Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92%
 Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a
- Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects".
 In: *Cureus* 14.8 (Aug. 31, 2022). Publisher: Cureus.
- [9] Catalina Jaramillo. "Clinical Trials Show Ivermectin Does Not Benefit COVID-19 Patients,
 Contrary to Social Media Claims". In: *FactCheck.org* (Sept. 15, 2022).
- ⁵⁵⁶ [10] "Fact Check-Gaps in study claiming that ivermectin reduces risk of COVID-19 death by
 ⁵⁵⁷ 92%". In: *Reuters* (Sept. 20, 2022).
- ⁵⁵⁸ [11] "Study claiming that ivermectin reduces COVID-19 mortality by 92% has important
 methodological problems". In: *Health Feedback* (Sept. 7, 2022).
- ⁵⁶⁰ [12] Author Adam Marcus. *Journal says ivermectin study met standard for 'credible science'*.
- Retraction Watch. Sept. 19, 2022. URL: https://retractionwatch.com/2022/09/19/journal-
- says-ivermectin-study-met-standard-for-credible-science/ (visited on 04/25/2023).

medRxiv preprint doi: https://doi.org/10.1101/2023.08.10.23293924; this version posted October 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

- ⁵⁶³ [13] Sander van der Linden. "Misinformation: susceptibility, spread, and interventions to
- immunize the public". In: *Nature Medicine* (Mar. 10, 2022). Publisher: Nature Publishing
 Group, pp. 1–8.
- ⁵⁶⁶ [14] Gordon Pennycook et al. "Shifting attention to accuracy can reduce misinformation
- online". In: *Nature* 592.7855 (Apr. 2021). Number: 7855 Publisher: Nature Publishing
 Group, pp. 590–595.
- [15] Kamila Janmohamed et al. "Interventions to Mitigate COVID-19 Misinformation: A
 Systematic Review and Meta-Analysis". In: *Journal of Health Communication* 26.12
- ⁵⁷¹ (Dec. 2, 2021). Publisher: Taylor & Francis _eprint:
- https://doi.org/10.1080/10810730.2021.2021460, pp. 846–857.
- ⁵⁷³ [16] Catalog of Bias Collaboration, H Lee, and D Nunan. "Immortal time bias". In: *Catalog of Bias*. May 16, 2020.
- [17] Catalog of Bias Collaboration, EA Spencer, and C Heneghan. "Chronological bias". In:
 Catalog of Bias. July 18, 2017.
- [18] Catalog of Bias Collaboration et al. "Attrition bias". In: Catalog of Bias. July 20, 2017.
- [19] D. L. Sackett. "Bias in analytic research". In: *Journal of Chronic Diseases* 32.1 (1979),
 pp. 51–63.
- [20] Grace Keegan, Angelena Crown, and Kathie-Ann Joseph. "Diversity, Equity, and
- Inclusion in Clinical Trials". In: *Surgical Oncology Clinics of North America* 32.1 (Jan. 2023), pp. 221–232.
- 583 [21] Stacy J. UyBico, Shani Pavel, and Cary P. Gross. "Recruiting Vulnerable Populations into
 Research: A Systematic Review of Recruitment Interventions". In: *Journal of General Internal Medicine* 22.6 (June 2007), pp. 852–863.
- [22] Abigail LaPlante et al. "Enrollment, retention, and strategies for including
 disadvantaged populations in randomized controlled trials: a systematic review
- ⁵⁸⁸ protocol". In: *Systematic Reviews* 10.1 (Aug. 18, 2021), p. 233.
- Alein Y. Haro-Ramos et al. "Frontline work and racial disparities in social and economic
 pandemic stressors during the first COVID-19 surge". In: *Health Services Research* (Jan. 31, 2023).
- Figure 124] Ricardo E. da Silva et al. "Factors Contributing to Exacerbating Vulnerabilities in Global
 Clinical Trials". In: *Frontiers in Pharmacology* 8 (2017), p. 999.
- ⁵⁹⁴ [25] Daniel T. Lackland et al. "Impact of COVID-19 on Clinical Research and Inclusion of ⁵⁹⁵ Diverse Populations". In: *Ethnicity & Disease* 30.3 (2020), pp. 429–432.
- Faulo Ricardo Martins-Filho et al. "COVID-19 fatality rates related to social inequality in
 Northeast Brazil: a neighbourhood-level analysis". In: *Journal of Travel Medicine* 27.7
 (Nov. 9, 2020), taaa128.
- [27] Carlos Dornels Freire de Souza, Rodrigo Feliciano do Carmo, and
 Michael Ferreira Machado. "The burden of COVID-19 in Brazil is greater in areas with
 high social deprivation". In: *Journal of Travel Medicine* 27.7 (Nov. 9, 2020), taaa145.
- 602 [28] Gabriela Drummond Margues da Silva et al. "Influência da desigualdade
- socioeconômica na distribuição das internações e dos óbitos por covid-19 em
- municípios brasileiros, 2020: um estudo ecológico Influência da desigualdade
- socioeconômica na distribuição das internações e dos óbitos por covid-19 em
- municípios brasileiros, 2020: um estudo ecológico". In: *Epidemiologia e servicos de saude*
- *i revista do Sistema Unico de Saude do Brasil* 32.1 (2023). Place: Brazil, e2022303.
- [29] Sander Greenland et al. "Statistical tests, P values, confidence intervals, and power: a
 guide to misinterpretations". In: *European Journal of Epidemiology* 31 (2016),
- 610 pp. 337–350.
- [30] Jimmie Leppink, Kal Winston, and Patricia O'Sullivan. "Statistical significance does not
- ⁶¹² imply a real effect". In: *Perspectives on Medical Education* 5.2 (Apr. 1, 2016), pp. 122–124.

medRxiv preprint doi: https://doi.org/10.1101/2023.08.10.23293924; this version posted October 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

- C. L. Bandt and J. R. Boen. "A prevalent misconception about sample size, statistical [31] 613 significance, and clinical importance". In: Journal of Periodontology 43.3 (Mar. 1972), 614 pp. 181-183. 615 [32] M. J. Turner and J. M. Schaeffer. "Mode of Action of Ivermectin". In: Ivermectin and 616
- Abamectin. Ed. by William C. Campbell. New York, NY: Springer, 1989, pp. 73–88. 617
- Mohammed Atif et al. "Effects of glutamate and ivermectin on single glutamate-gated [33] 618 chloride channels of the parasitic nematode H. contortus". In: PLoS Pathogens 13.10 619 (Oct. 2017). Publisher: PLOS. 620
- Kylie M. Wagstaff et al. "Ivermectin is a specific inhibitor of importin α/β -mediated [34] 621 nuclear import able to inhibit replication of HIV-1 and dengue virus". In: Biochemical 622 Journal 443.3 (Apr. 16, 2012), pp. 851-856. 623
- Sundy N. Y. Yang et al. "The broad spectrum antiviral ivermectin targets the host [35] 624 nuclear transport importin α/β 1 heterodimer". In: Antiviral Research 177 (May 1, 2020), 625 p. 104760. 626
- [36] Nilima Dinesh Kumar et al. "Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication 627 in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells". In: Antimicrobial 628 Agents and Chemotherapy 66.1 (Jan. 18, 2022). Publisher: American Society for 629 Microbiology, e01543-21.
- 630
- Ricardo Peña-Silva et al. "Pharmacokinetic considerations on the repurposing of [37] 631 ivermectin for treatment of COVID-19". In: British Journal of Clinical Pharmacology 87.3 632 (2021). _eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14476, 633
- pp. 1589-1590. 634
- Aránzazu González Canga et al. "The Pharmacokinetics and Interactions of Ivermectin [38] 635 in Humans—A Mini-review". In: The AAPS Journal 10.1 (Jan. 25, 2008), pp. 42-46. 636
- Sara Reardon. "Flawed ivermectin preprint highlights challenges of COVID drug studies". [39] 637 In: Nature 596.7871 (Aug. 2, 2021). Bandiera abtest: a Cg type: News Number: 7871 638 Publisher: Nature Publishing Group Subject_term: Research data, SARS-CoV-2, Public 639
- health, Publishing, pp. 173-174.
- Gideon Meyerowitz-Katz et al. "Unethical studies of ivermectin for covid-19". In: BM/ 377 [40] 641 (Apr. 14, 2022). Publisher: British Medical Journal Publishing Group Section: Editorial, 642 o917. 643
- Andrew Hill et al. "Retraction to: Meta-analysis of Randomized Trials of Ivermectin to [41] 644 Treat SARS-CoV-2 Infection". In: Open Forum Infectious Diseases 9.3 (Mar. 2022), ofac056. 645
- Pierre Kory et al. "Review of the Emerging Evidence Demonstrating the Efficacy of [42] 646 Ivermectin in the Prophylaxis and Treatment of COVID-19". In: American Journal of Therapeutics 28.3 (June 2021), e299. 648
- [43] Gabriela Buffet, Raul Mendoza-Sassi, and Marinos Fysekidis. "Inaccurate Real-World 649 Data Does Not Provide Real-World Answers". In: American Journal of Therapeutics 28.5 650 (lune 29, 2021), e596-e598. 651
- Jack M. Lawrence et al. "The lesson of ivermectin: meta-analyses based on summary [44] 652 data alone are inherently unreliable". In: Nature Medicine 27.11 (Nov. 2021). Number: 11 653 Publisher: Nature Publishing Group, pp. 1853–1854. 654
- Kyle A. Sheldrick, Gideon Meyerowitz-Katz, and Greg Tucker-Kellogg. "Plausibility of [45] 655 Claimed Covid-19 Vaccine Efficacies by Age: A Simulation Study". In: American Journal of 656 Therapeutics (2022). 657
- Steven Chee Loon Lim et al. "Efficacy of Ivermectin Treatment on Disease Progression [46] 658 Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH 659
- Randomized Clinical Trial". In: JAMA Internal Medicine (Feb. 18, 2022). 660
- [47] Gilmar Reis et al. "Effect of Early Treatment with Ivermectin among Patients with 661
- Covid-19". In: New England Journal of Medicine 0.0 (Mar. 30, 2022). Publisher: 662
- Massachusetts Medical Society _eprint: https://doi.org/10.1056/NEJMoa2115869, null. 663

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

- [48] Susanna Naggie et al. "Effect of Ivermectin vs Placebo on Time to Sustained Recovery in
 Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial". In: *JAMA* 328.16 (Oct. 25, 2022), pp. 1595–1603.
- 667 [49] Carolyn T. Bramante et al. "Randomized Trial of Metformin, Ivermectin, and
- Fluvoxamine for Covid-19". In: *The New England Journal of Medicine* 387.7 (Aug. 18, 2022),
 pp. 599–610.
- ⁶⁷⁰ [50] Susanna Naggie et al. "Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time
 ⁶⁷¹ to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial". In:
 ⁶⁷² JAMA 329.11 (Mar. 21, 2023), pp. 888–897.
- ⁶⁷³ [51] Maria Popp et al. "Ivermectin for preventing and treating COVID-19". In: *Cochrane* ⁶⁷⁴ *Database of Systematic Reviews* 6 (2022). Publisher: John Wiley & Sons, Ltd.
- [52] Redação MPV. *Greg Tucker-Kellogg publishes fraudulent study to attack ivermectin*.
 Medicos Pela Vida. Aug. 17, 2023. URL:
- https://medicospelavidacovid19.com.br/editoriais/greg-tucker-kellogg-publishes-fraudulent study-to-attack-ivermectin/ (visited on 09/24/2023).
- [53] Redação MPV. Médica publica estudo fraudulento para atacar pesquisa da ivermectina em
 Itajaí. Medicos Pela Vida. Aug. 17, 2023. URL:
- https://medicospelavidacovid19.com.br/editoriais/medica-publica-estudo-fraudulento-para atacar-pesquisa-da-ivermectina-em-itajai/ (visited on 09/24/2023).
- [54] A. Tversky and D. Kahneman. "Judgment under uncertainty: Heuristics and biases". In:
 Science 185.4157 (1974), pp. 1124–1131.
- [55] Pedro Bordalo, Nicola Gennaioli, and Andrei Shleifer. "Salience Theory of Choice Under
 Risk". In: *The Quarterly Journal of Economics* 127.3 (Aug. 1, 2012), pp. 1243–1285.
- [56] Pedro Bordalo, Nicola Gennaioli, and Andrei Shleifer. "Salience and consumer choice".
 In: *Journal of Political Economy* 121.5 (2013). Publisher: University of Chicago Press
 Chicago, IL, pp. 803–843.
- [57] Andrew Gelman and Eric Loken. "The statistical crisis in science". In: *American Scientist* 102.6 (2014). Publisher: Sigma XI-The Scientific Research Society, p. 460.
- [58] Peter Mueser and Donald Granberg. *The Monty Hall Dilemma Revisited: Understanding the Interaction of Problem Definition and Decision Making*. Experimental. University
 Library of Munich, Germany, 1999.
- In Solving the Monty Hall Dilemma: A Systematic
 Review". In: *Psychologica Belgica* 58.1 (June 1, 2018). tex.ids=
 saenenWhyHumansFail2018a, pp. 128–158.
- "TCE pede explicações à prefeitura de Itajaí sobre distribuição de ivermectina; médicos
 dividem opinião sobre uso contra Covid-19". In: *globo.com* (July 31, 2020),
- https://g1.globo.com/sc/santa-catarina/noticia/2020/07/31/tce-pede-explicacoes-a-
- prefeitura-de-itajai-sobre-compra-e-distribuicao-de-antiparasitario-medicos dividem-opiniao-sobre-uso-contra-covid-19.ghtml.
- [61] Ke Men et al. "Estimate the incubation period of coronavirus 2019 (COVID-19)." In:
 Computers in biology and medicine 158 (May 2023). Place: United States, p. 106794.
- ⁷⁰⁵ [62] Long V. Bui et al. "Estimation of the incubation period of COVID-19 in Vietnam." In: *PloS*
- one 15.12 (2020). Place: United States, e0243889.
- [63] Giacomo Grasselli et al. "Hospital-Acquired Infections in Critically III Patients With
 COVID-19." In: *Chest* 160.2 (Aug. 2021). Place: United States, pp. 454–465.
- ⁷⁰⁹ [64] Tomas J. Aragon. *epitools: Epidemiology tools*. manual. 2020.